＜論文・著書＞*corresponding author, #equal contribution
1. Fukudo S*, Nakaya K, Muratsubaki T, Nakaya N, Hozawa A, Bangdiwala SI, Palsson OS, Sperber AD, Kanazawa M. Characteristics of disorders of gut-brain interaction in the Japanese population in the Rome Foundation Global Epidemiological Study. Neurogastroenterol Motil 35(6): e14581, 2023.
2. Sugiura M*, Katayori Y#, Muratsubaki T, Shiratori M, Hanawa S, Nejad KK, Tamura D, Kawashima R, Fukudo S. Automatic adaptive emotion regulation is associated with lower emotion-related activation in the frontoparietal cortex and other cortical regions with multi-componential organization. Front Behav Neurosci 17: 1059158, 2023.
3. Gearry R*, Fukudo S, Barbara G, Kuhn-Sherlock B, Ansell J, Blatchford P, Eady S, Wallace A, Butts C, Cremon C, Raffaella Barbaro M, Pagano I, Candela M, Turroni S, Okawa Y, Muratubaki T, Okamoto T, Fuda M, Endo Y, Kano M, Kanazawa M, Nakaya N, Nakaya K, Drummond L. Consumption of 2 green kiwifruit daily improves constipation and abdominal comfort – results of an international multicentre randomised controlled trial. Am J Gastroenterol 2023 Jan 9. doi: 10.14309/ajg.0000000000002124. Online ahead of print. PMID: 36537785.
4. Takeoka A, Kimura T, Hara S, Hamaguchi T, Fukudo S, Tayama J*. Prevalence of irritable bowel syndrome in Japan, China, and South Korea: An international cross-sectional study. J Neurogastroenterol Motil 29(2): 229-237, 2023.
5. Sperber AD*, Bor S, Fang X, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, Whitehead WE, Dumitrascu DL, Fukudo S, et al. Face-to-face interviews versus Internet surveys: Comparison of two data collection methods in the Rome foundation global epidemiology study: Implications for population-based research. Neurogastroenterol Motil 35(6): e14583, 2023.
6. Hreinsson JP*, Wong RKM, Tack J, Whorwell P, Benninga MA, Andresen V, Bonaz B, Choi SC, Corazziari ES, Santos J, Fukudo S, Kanazawa M, Fang X, Bangdiwala SI, Sperber AD, Palsson OS, Simrén M. A comparative study of disorders of gut-brain interaction in Western Europe and Asia based on the Rome foundation global epidemiology study. Neurogastroenterol Motil 35(6): e14566, 2023.
7. Hasegawa R, Saito-Nakaya K, Gu L, Kanazawa M, Fukudo S*. Maternal separation and TNBS-induced gut inflammation synergistically alter the sexually differentiated stress response in rats. Biopsychosoc Med 17(1): 7, 2023.
8. Tanaka Y, Yamashita R#, Kawashima J, Mori H, Kurokawa K, Fukuda S, Gotoh Y, Nakamura K, Hayashi T, Kasahara Y, Sato Y, Fukudo S*. Further notice of omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation. J Gastroenterol 58(4): 427-428, 2023.
9. Koseki T*, Muratsubaki T, Tsushima H, Morinaga Y, Oohashi T, Imafuku M, Suzuki Y, Kanazawa M, Fukudo S. Impact of mindfulness tendency and physical activity on brain-gut interactions. J Gastroenterol 58(2): 158-170, 2023.
10. Fukudo S*, Kano M, Sato Y, Muratsubaki T, Kanazawa M, Tashiro M, Yanai K. Histamine neuroimaging in stress-related disorders. Curr Top Behav Neurosci 59: 113-130, 2022.
11. Tanaka Y, Yamashita R#, Kawashima J, Mori H, Kurokawa K, Fukuda S, Gotoh Y, Nakamura K, Hayashi T, Kasahara Y, Sato Y, Fukudo S*. Omics profiles of fecal and oral microbiota change in irritable bowel syndrome patients with diarrhea and symptom exacerbation. J Gastroenterol 57(10): 748-760, 2022.
12. Koizumi K, Hamaguchi T*, Tayama J, Fukudo S. A method of generating a classifier that determines the presence or absence of IBS symptoms by supervised learning from the frequency analysis of electroencephalogram data. Front Biosci (Landmark Ed) 27(6): 187, 2022.
13. Otani K*, Watanabe T, Higashimori A, Suzuki H, Kamiya T, Shiotani A, Sugimoto M, Nagahara A, Fukudo S, Motoya S, Yamaguchi S, Zhu Q, Chan FKL, Hahm KB, Tablante MC, Prachayakul V, Abdullah M, Ang TL, Murakami K; International Gastrointestinal Consensus Symposium Study Group. A questionnaire-based survey on the impact of the COVID-19 pandemic on gastrointestinal endoscopy in Asia. Digestion 103(1): 7-21, 2022.
14. Fukudo S*, Okumura T, Inamori M, Okuyama Y, Kanazawa M, Kamiya T, Sato K, Shiotani A, Naito Y, Fujikawa Y, Hokari R, Masaoka T, Fujimoto K, Kaneko H, Torii A, Matsueda K, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. J Gastroenterol 56: 193-217, 2021.
15. Funaba M, Kawanishi H, Fujii Y, Higami K, Tomita Y, Maruo K, Sugawara N, Oe Y, Kura S, Horikoshi M, Ohara C, Kikuchi H, Ariga H, Fukudo S, Sekiguchi A, Ando T*. Hybrid cognitive behavioral therapy with interoceptive exposure for irritable bowel syndrome: A feasibility study. Front Psychiatry 12: 673939, 2021.
16. Sperber AD*, Freud T, Aziz I, Palsson OS, Drossman DA, Dumitrascu DL, Fang X, Fukudo S, Ghoshal UC, Kellow J, Khatun R, Okeke E, Quigley EMM, Schmulson M, Simren M, Tack J, Whitehead WE, Whorwell P, Bangdiwala SI. Greater overlap of Rome IV disorders of gut-brain interactions leads to increased disease severity and poorer quality of life. Clin Gastroenterol Hepatol 20(5): e945-e956, 2021.
17. Aizawa Y, Morishita J, Kano M, Kanazawa M, Fukudo S*. Modification of rectal function and emotion by repetitive transcranial magnetic stimulation in humans. Neurosci Res 168: 54-63, 2021.
18. Tsushima H, Zhang Y, Muratsubaki T, Kanazawa M, Fukudo S*. Oxytocin antagonist induced visceral pain and corticotropin-releasing hormone neuronal activation in the central nucleus of the amygdala during colorectal distention in mice. Neurosci Res 168: 41-53, 2021.
19. Yagihashi M, Kano M, Muratsubaki T, Morishita J, Kono K, Tanaka Y, Kanazawa M, Fukudo S*. Concordant pattern of the HPA axis response to visceral stimulation and CRH administration. Neurosci Res 168: 32-40, 2021.
20. Sperber AD*, Bangdiwala SI, Drossman DA, Ghoshal UC, Imren M, Tack J, Whitehead WE, Dumitrascu DL, Fang X, Fukudo S, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation global study. Gastroenterology 160(1):99-114.e3, 2021.
21. Fukudo S*, Nakamura M, Hamatani T, Kazumori K, Miwa H. Efficacy and safety of 5-HT4 receptor agonist minesapride for irritable bowel syndrome with constipation in a randomized controlled trial. Clin Gastroenterol Hepatol 19(3): 538-546.e8, 2021.
22. Hamatani S, Hirano Y, Sugawara A, Isobe M, Kodama N, Yoshihara K, Moriguchi Y, Ando T, Endo Y, Takahashi J, Nohara N, Takamura T, Hori H, Noda T, Tose K, Watanabe K, Adachi H, Gondo M, Takakura S, Fukudo S, Shimizu E, Yoshiuchi K, Sato Y, Sekiguchi A*. Eating Disorder Neuroimaging Initiative (EDNI): a multicentre prospective cohort study protocol for elucidating the neural effects of cognitive-behavioural therapy for eating disorders. BMJ Open 11(1): e042685, 2021.
23. Hamatani T*, Fukudo S#, Nakada Y, Inada H, Kazumori K, Miwa H. Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation. Aliment Pharmacol Ther 52(3): 430-441, 2020.
24. Hamatani T*, Fukudo S, Nakada Y, Inada H, Kazumori K, Miwa H. Editorial: minesapride for irritable bowel syndrome with constipation-authors' reply. Aliment Pharmacol Ther 52(4): 715-716, 2020.
25. Hamaguchi T*, Tayama J, Suzuki M, Nakaya N, Takizawa H, Koizumi K, Amano Y, Kanazawa M, Fukudo S. The effects of locomotor activity on gastrointestinal symptoms of irritable bowel syndrome among younger people: An observational study. PLoS One 15(5) :e0234089, 2020.
26. Hamatani T*, Fukudo S, Nakada Y, Inada H, Kazumori K, Miwa H. Letter: placebo run-in for IBS clinical trials - is it useful? Authors' reply. Aliment Pharmacol Ther 52(7): 1239-1240, 2020.
27. Van Oudenhove L, Kragel PA#, Dupont P, Ly HG, Pazmany E, Enzlin P, Rubio A, Delon-Martin C, Bonaz B, Aziz Q, Tack J, Fukudo S, Kano M, Wager TD*. Common and distinct neural representations of aversive somatic and visceral stimulation in healthy individuals. Nature Commun 11(1): 5939, 2020.
28. Kano M*, Grinsvall C, Ran Q, Dupont P, Morishita J, Muratsubaki T, Mugikura S, Ly HG, Törnblom H, Ljungberg M, Takase K, Simrén M, Van Oudenhove L, Fukudo S. Resting state functional connectivity of the pain matrix and default mode network in irritable bowel syndrome: a graph theoretical analysis. Sci Rep 10(1): 11015, 2020.
29. Kano M*, Muratsubaki T, Yagihashi M, Morishita J, Mugikura S, Dupont P, Takase K, Kanazawa M, Van Oudenhove L, Fukudo S. Insula activity to visceral stimulation and endocrine stress responses as associated with alexithymia in patients with irritable bowel syndrome. Psychosom Med 82: 29-38, 2020.
30. Kano M*, Oudenhove LV, Dupont P, Wager TD, Fukudo S. Imaging brain mechanisms of functional somatic syndromes: potential as a biomarker? Tohoku J Exp Med 250(3): 137-152, 2020.
31. Fukudo S*, Miwa H, Nakajima A, Kinoshita Y, Kosako M, Hayashi K, Akiho H, Kuroishi K, Johnston JM, Currie M, Ohkusa T. High-dose linaclotide is effective and safe in patients with chronic constipation: A phase III randomized, double-blind, placebo-controlled study with a long-term open-label extension study in Japan. Neurogastroenterol Motil 31 (1): e13487, 2019.
32. Kawanishi H, Sekiguchi A, Funaba M, Fujii Y, Yoshiuchi K, Kikuchi H, Kawai K, Maruo K, Sugawara N, Hatano K, Shoji T, Yamazaki T, Toda K, Murakami M, Shoji M, Ohara C, Tomita Y, Fukudo S, Ando T*. Cognitive behavioral therapy with interoceptive exposure and complementary video materials for irritable bowel syndrome (IBS): protocol for a multicenter randomized controlled trial in Japan. BioPsychoSoc Med 13:14, 2019.
33. Kano M*, Yoshizawa M, Kono K, Muratsubaki T, Morishita J, Van Oudenhove L, Yagihashi M, Mugikura S, Dupont P, Takase K, Kanazawa M, Fukudo S. Parasympathetic activity correlates with subjective and brain responses to rectal distension in healthy subjects but not in non-constipated patients with irritable bowel syndrome. Sci Rep 9 (1): 7358, 2019.
34. Fukudo S*, Kaku K. Effect of mizagliflozin on postprandial plasma glucose in patients with functional constipation. J Neurogastroenterol Motil 25 (2): 332-333, 2019.
35. Fukudo S*, Kaku K. Future possibility of mizagliflozin on functional constipation and/or irritable bowel syndrome with constipation. Gastroenterology 157 (3): 898-899, 2019.
36. Fukudo S*, Endo Y, Hongo M, Nakajima A, Abe T, Kobayashi H, Nakata T, Nakajima T, Sameshima K, Kaku K; Mizagliflozin Study Group. Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial. Lancet Gastroenterol Hepatol 3 (9): 603-613, 2018.
＜特許権等知的財産権の取得及び申請状況＞
特願2015-29188 過敏性腸症候群の診断用バイオマーカー、 IBS Rome IV質問紙日本語版、IBS-QOL質問紙日本語版、IBS-重症度指標質問紙日本語版
＜政策提言＞
機能性消化管疾患（過敏性腸症候群）診療ガイドライン（日本消化器病学会編、日本消化管学会、日本神経消化器病学会、日本心身医学会協力、2020年）
＜資金制度・研究費名＞
2021年-2025年 ムーンショット型研究開発事業（AMED）ミトコンドリア先制医療(代表 阿部高明）(分担 福土審）4,200千円/年 [21,000千円予定]
2023年-2028年 科学研究費補助金・基盤C研究（日本学術振興会）過敏性腸症候群における特異的神経回路の決定因子（代表 福土審）700千円/年 [3,500千円予定]
2018年-2024年 東北大学-ビオフェルミン製薬共同研究事業 (代表 福土審) 42,645千円 過敏性腸症候群における腸内細菌の研究
2018年-2024年 東北大学-株式会社ツムラ共同研究事業 (代表 福土審) 44,488千円 過敏性腸症候群に対する抑肝散加陳皮半夏の介入研究
2020年-2024年 喫煙科学研究財団研究費 (代表 福土審) 10,000千円 過敏性腸症候群と関連疾患における脳腸相関に対する腸内細菌と喫煙・生活習慣の役割.
2019年-2024年 AMED戦略的国際脳科学研究推進プログラム (代表 関口 敦) 摂食障害に対する認知行動療法の有効性の神経科学的エビデンスの創出
